Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by E.L. Simpson
Conjunctivitis in Moderate-to-severe Atopic Dermatitis
Abstract and Introduction Abstract Background: Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds with high affinity to interleukin-13, effectively reduces moderate-to-severe atopic dermatitis (AD) when given every 2 weeks. The incidence of conjunctivitis is elevated vs. placebo, but severity and aetiology have not been examined.
Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials
Summary Background Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds with high affinity to interleukin-13, effectively reduces moderate-to-severe atopic dermatitis (AD) when given every 2 weeks. The incidence of conjunctivitis is elevated vs. placebo, but severity and aetiology have not been examined. Objective To analyse conjunctivitis data recorded in five randomized, placebo-controlled trials of tralokinumab in adult patients with moderate-to-severe AD.
评估接受 Dupilumab 治疗的中度至重度特应性皮炎患者进行常规安全性检测的必要性
Summary 特应性皮炎(又称 AD 或湿疹)是一种常见的皮肤病,可引起强烈和持续的瘙痒和皮疹。对于一些中度至重度 AD 患者来说,护肤霜或软膏不合适或不起效。这些患者可能需要口服或注射药物。 其中一些口服或注射治疗可能具有毒性,常常会产生不想要的副作用,特别是在使用时间较长的情况下,因此必须定期对患者进行检测,查看这些治疗是否在损害他们的血液或器官。 Dupilumab 是一种治疗中度至重度 AD 的较新的注射药物。Dupilumab 专门作用于体内导致 AD 的关键分子。在安慰剂对照临床试验中已经在 2000 多名患者身上对 Dupilumab 进行了长达一年的测试。在这些试验中,患者在接受 Dupilumab 或安慰剂(模拟药物)治疗时提供血液和尿液样本进行实验室检测。 本文中,来自德国和美国的作者分析了血细胞、血生化和尿生化在治疗过程中的变化,以检查是否可以在不需要进行定期实验室检测的情况下安全地使用 Dupilumab。 在对患者的血液和尿液进行了许多常规实验室检测后,他们发现,检测结果中没有可能与 Dupilumab 有关的临床重要变化。因此得出结论,使用...
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate‐to‐severe atopic dermatitis
Summary Atopic dermatitis (also known as AD or eczema) is a common skin disease that can cause intense and persistent itching and rashes. Skin creams or ointments are not suitable or effective for some patients with moderate‐to‐severe AD. In these patients, oral (taken by mouth) or injected medications may be required.
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Clinical Trial E.L. Simpson Corresponding Author simpsone@ohsu.edu Department of Dermatology, Oregon Health and Science University, Portland, OR, USA Correspondence Eric L. Simpson. Email: simpsone@ohsu.edu Search for more papers by this author K.
Conjunctivitis in dupilumab clinical trials
Summary Conjunctivitis is a common condition that causes the eye to become red, itchy and oozing. It is common in patients with atopic dermatitis (also called eczema), and in other allergic diseases, including asthma. Apart from allergies, conjunctivitis can also be caused by infections, chemicals, irritants, and other diseases.
Dupilumab 临床试验中的结膜炎
Summary 结膜炎是一种导致眼睛变红、瘙痒和渗出的常见疾病。它在特应性皮炎(也称为湿疹)和其他过敏性疾病(包括哮喘)的患者中常见。除了过敏,感染、化学品、刺激物和其他疾病也可引起结膜炎。Dupilumab 是一种处方药,在美国批准用于不能通过局部外用(外用到皮肤)处方药控制或不能局部外用药物的≥ 12 岁中重度 AD 患者,在其他国家批准用于通过现有治疗无法控制的 AD 成人,和用于通过当前用药无法控制的≥12 岁中重度哮喘患者的维持治疗。Dupilumab 可阻滞导致这些过敏性疾病的特定物质的活性。在大部分 AD 研究中,接受dupilumab治疗患者中的结膜炎发生率多于安慰剂(模拟药物)组。为了研究这一作用,作者们评估了在 AD、哮喘、慢性鼻窦炎伴鼻息肉(CRSwNP) 和嗜酸性粒细胞性食管炎(EoE) 中开展的 11 项 dupilumab 研究中的结膜炎的发生率、风险因素、严重程度和结局。在 6 项 AD 研究的 5 项中,dupilumab治疗患者较安慰剂治疗患者更容易发生结膜炎。没有确认因感染导致的结膜炎,其性质似乎也不是过敏性的。进入这些研究时 AD...
Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS) - Wollenberg - - British Journal of Dermatology - Wiley Online Library
Original Article Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS) A.
Conjunctivitis in dupilumab clinical trials
Summary Background Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13.
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from 2 phase III trials - Silverberg - - British J
The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials - Silverberg - 2019 - Br
Clinical Trial Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials J.I. Silverberg Corresponding Author E-mail address: jonathanisilverberg@gmail.com https://orcid.org/0000-0003-3686-7805 Department of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine,...
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomic regions: data from phase 3 clinical trials
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Research Letter Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomic regions: data from phase 3 clinical trials A.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with E.L.
Contact E.L., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack